Table 2 Observed weekly transition relative frequencies (%) between the eight health states from the first four weeks of the RGH-188-005 clinical trial
From [row] / to [col] | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | n |
|---|---|---|---|---|---|---|---|---|---|
Risperidone | |||||||||
1 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 |
2 | 3.31 | 80.99 | 0.00 | 9.09 | 5.79 | 0.83 | 0.00 | 0.00 | 121 |
3 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 |
4 | 0.00 | 22.10 | 0.55 | 74.31 | 0.83 | 2.21 | 0.00 | 0.00 | 362 |
5 | 0.00 | 16.07 | 0.00 | 3.57 | 75.00 | 5.36 | 0.00 | 0.00 | 56 |
6 | 0.00 | 2.87 | 0.00 | 8.91 | 12.07 | 76.15 | 0.00 | 0.00 | 348 |
7 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
8 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
Cariprazine | |||||||||
1 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3 |
2 | 6.03 | 87.07 | 0.00 | 5.17 | 1.72 | 0.00 | 0.00 | 0.00 | 116 |
3 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 |
4 | 0.00 | 19.89 | 0.27 | 75.33 | 0.53 | 3.98 | 0.00 | 0.00 | 377 |
5 | 0.00 | 22.92 | 0.00 | 0.00 | 70.83 | 6.25 | 0.00 | 0.00 | 48 |
6 | 0.00 | 3.51 | 0.00 | 11.99 | 10.53 | 73.98 | 0.00 | 0.00 | 342 |
7 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
8 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0 |